Laboratory Evaluation and Diagnostic Algorithm for Hyperthyroidism

Initial Screening

• Serum TSH should be obtained first and is the most reliable initial screening indicator for thyroid dysfunction; a normal TSH effectively rules out hyperthyroidism in virtually all patients. (American College of Endocrinology) 1
• If TSH is suppressed, free T4 and total T3 must be measured immediately to confirm hyperthyroidism and to differentiate T4‑predominant from T3‑predominant thyrotoxicosis. (American Association of Clinical Endocrinologists) 2

Reflex Testing When TSH Is Suppressed

• Free T4 assessment quantifies the degree of hormone excess and distinguishes overt from subclinical hyperthyroidism. (American Association of Clinical Endocrinologists) 2
• Total T3 measurement is preferred over free T3 because total T3 assays have superior methodological validation and are specifically recommended by the American Association of Clinical Endocrinologists. (AACE) 3
• Total T3 testing detects T3‑predominant thyrotoxicosis, which can occur even when free T4 is normal or only mildly elevated. (American College of Endocrinology) 1

Confirmation of Persistent Abnormalities

• Repeat TSH, free T4, and total T3 within 4 weeks to verify persistent suppression before initiating extensive work‑up or therapy; transient abnormalities do not require treatment. (American Association of Clinical Endocrinologists) 4

Etiologic Testing After Biochemical Confirmation

TSH‑Receptor Antibody (TRAb)

• TRAb should be measured when clinical features suggest Graves’ disease (diffuse goiter, ophthalmopathy, dermopathy); a positive result essentially confirms Graves’ disease and can obviate radioactive iodine uptake scanning. (American Association of Clinical Endocrinologists) 2

Radioactive Iodine Uptake (RAIU) and Thyroid Scan

• RAIU is indicated when the clinical picture is not diagnostic of Graves’ disease or when TRAb is negative. (American College of Endocrinology) 1
• Add a thyroid scan if nodularity is detected on physical examination or ultrasound. (American College of Endocrinology) 1
• RAIU differentiates causes with elevated/normal uptake (e.g., Graves’ disease, toxic nodular goiter) from those with near‑absent uptake (e.g., thyroiditis, exogenous hormone, amiodarone‑induced thyroiditis). (American College of Endocrinology) 1

Anti‑Thyroid Peroxidase Antibody (Anti‑TPO)

• Anti‑TPO testing is appropriate when autoimmune thyroiditis is suspected as the cause of transient thyrotoxicosis (painless thyroiditis). (American Association of Clinical Endocrinologists) 2
• Anti‑TPO is positive in most cases of Hashimoto’s thyroiditis but does not differentiate destructive thyroiditis from Graves’ disease. (American Association of Clinical Endocrinologists) 2

Thyroid Ultrasound

• A normal thyroid ultrasound makes toxic nodular disease less likely, although it does not exclude it. (American Association of Clinical Endocrinologists) 4

Critical Pitfalls to Avoid

• Never diagnose hyperthyroidism on a single TSH result; always confirm with repeat testing and measurement of thyroid hormones. (American Association of Clinical Endocrinologists) 4
• Do not order free T3 when TSH is normal, because a normal TSH excludes hyperthyroidism in virtually all cases. (American Association of Clinical Endocrinologists) 3
• Exclude assay interferences (heterophilic antibodies, biotin supplementation, heparin therapy) when biochemical results are discordant with clinical presentation. (American College of Endocrinology) 1
• Do not rely on TSH alone; an elevated total T4 with normal TSH may represent euthyroid hyperthyroxinemia due to binding‑protein abnormalities rather than true hyperthyroidism. (American College of Endocrinology) 1
• Avoid routine TSH testing in hospitalized patients unless there is a clear clinical indication, as non‑thyroidal illness can produce misleading results. (American Association of Clinical Endocrinologists) 2
• Recognize that T3‑predominant thyrotoxicosis (elevated T3 with normal T4) constitutes overt hyperthyroidism requiring definitive treatment, not subclinical disease. (American Association of Clinical Endocrinologists) 3

Special Considerations

• During pregnancy, use total T4 or a free T4 index with trimester‑specific reference ranges because standard free T4 assays are less reliable in gestation. (American Association of Clinical Endocrinologists) 2
• If free T4 is elevated while TSH is normal or elevated, evaluate for TSH‑producing pituitary adenoma (MRI, α‑subunit measurement) and for thyroid‑hormone resistance (family history, genetic testing). (American College of Endocrinology) 1
• Spurious free T4 elevations can occur with heparin therapy, amiodarone, high‑dose propranolol, and acute psychosis; interpret results cautiously in these contexts. (American College of Endocrinology) 1

Laboratory Diagnosis of Hyperthyroidism

Overt Hyperthyroidism (Biochemical Confirmation)

• In overt hyperthyroidism, serum TSH is markedly suppressed (typically < 0.1 mIU/L), free T4 is above the upper reference limit, and total T3 is also elevated, confirming overt disease. 5

Subclinical Hyperthyroidism

• Subclinical hyperthyroidism is characterized by a suppressed TSH (generally 0.1–0.45 mIU/L, and may be < 0.1 mIU/L) while both free T4 and total T3 remain within their normal reference ranges. 6

Graves Disease Antibody Testing

• Approximately 5 % of patients newly diagnosed with Graves’ hyperthyroidism have a negative TSH‑receptor antibody (TRAb) result, most often in milder disease presentations. 5

Pregnancy‑Specific Laboratory Evaluation

• During pregnancy, hyperthyroidism is diagnosed using serum TSH together with either total T4 and total T3 (with reference ranges multiplied by ≈ 1.5 × non‑pregnant values) or free T4 and free T3 with trimester‑specific reference ranges. [5][7]
• In early pregnancy, a physiologically suppressed TSH with a normal free T4 reflects normal hCG‑mediated thyroid stimulation and does not indicate true hyperthyroidism. [5][7]
• In the second half of pregnancy, the non‑pregnant lower limit for TSH can be applied for interpretation. [5][7]

Biochemical Confirmation and Etiologic Workup of Hyperthyroidism

1. Initial Biochemical Screening

• A suppressed serum TSH (typically < 0.4 mIU/L, acknowledging laboratory‑specific reference ranges) indicates possible hyperthyroidism and should be confirmed with repeat testing and measurement of free T4 and total T3. 8

2. Potential Laboratory Interferences

• Heterophilic antibodies, high‑dose biotin supplementation, and heparin therapy can cause falsely low TSH or spuriously altered thyroid hormone results; clinicians should assess for these interferences when results are inconsistent with the clinical picture. 8

3. Role of Thyrotropin‑Receptor Antibody (TRAb)

• When features such as diffuse goiter, ophthalmopathy, or dermopathy suggest Graves’ disease, a positive TRAb essentially confirms the diagnosis and can eliminate the need for radioactive iodine uptake (RAIU) imaging.

4. Radioactive Iodine Uptake (RAIU) and Thyroid Scintigraphy

• The American College of Endocrinology and the American Association of Clinical Endocrinologists recommend performing RAIU (with or without a concurrent thyroid scan) when the clinical presentation is not clearly diagnostic for Graves’ disease or when TRAb testing is negative. 9
• If physical examination or ultrasound reveals nodularity, a thyroid scan should be added to the RAIU study to differentiate focal from diffuse uptake patterns. 9

4.1 Interpretation of RAIU Results

These uptake thresholds guide differentiation between hyperfunctioning thyroid disease and thyroiditis‑related thyrotoxicosis. 9

4.2 Ultrasound Guidance

• Thyroid ultrasound is advised when nodularity is suspected; a normal ultrasound makes toxic nodular disease less likely and helps decide whether a thyroid scan is necessary. 9

4.3 Pregnancy Considerations

• RAIU is contraindicated during pregnancy; in pregnant patients, clinicians should rely on clinical assessment and TRAb testing rather than radionuclide imaging.

All statements are derived from peer‑reviewed sources and reflect current recommendations of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

Recommendations Against Routine TRAb Testing in Subclinical Thyroid Disease

Guideline Recommendations

• The 2004 JAMA guidelines advise against routine thyroid‑stimulating hormone receptor antibody (TRAb) testing in patients with subclinical thyroid disease (i.e., suppressed TSH with normal free T4 and normal total T3), stating that expert opinion suggests the potential harms of unnecessary testing outweigh any benefit. 10